What is Lifesci Capital’s Estimate for SLNO Q3 Earnings?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at Lifesci Capital boosted their Q3 2026 earnings per share estimates for Soleno Therapeutics in a research report issued to clients and investors on Wednesday, November 5th. Lifesci Capital analyst K. Dellorusso now expects that the company will post earnings of $0.72 per share for the quarter, up from their prior forecast of $0.63. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q4 2026 earnings at $0.89 EPS.

A number of other equities research analysts also recently weighed in on the company. The Goldman Sachs Group set a $125.00 target price on Soleno Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Guggenheim restated a “buy” rating and set a $106.00 target price on shares of Soleno Therapeutics in a research report on Wednesday, August 27th. Robert W. Baird set a $121.00 price target on shares of Soleno Therapeutics and gave the stock an “outperform” rating in a research report on Friday, July 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Wednesday, October 8th. Finally, Oppenheimer lifted their target price on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Soleno Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $114.50.

Soleno Therapeutics Stock Performance

SLNO stock opened at $47.70 on Thursday. The company has a 50 day moving average price of $62.30 and a 200 day moving average price of $72.92. Soleno Therapeutics has a fifty-two week low of $41.50 and a fifty-two week high of $90.32. The company has a debt-to-equity ratio of 0.21, a current ratio of 15.13 and a quick ratio of 15.01. The stock has a market capitalization of $2.54 billion, a PE ratio of -11.52 and a beta of -2.92.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The company had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million.

Hedge Funds Weigh In On Soleno Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in Soleno Therapeutics during the 2nd quarter worth $25,000. Nisa Investment Advisors LLC raised its position in shares of Soleno Therapeutics by 287.8% during the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after purchasing an additional 400 shares during the period. AlphaQuest LLC lifted its holdings in shares of Soleno Therapeutics by 37.5% during the 1st quarter. AlphaQuest LLC now owns 983 shares of the company’s stock valued at $70,000 after purchasing an additional 268 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Soleno Therapeutics by 97.7% during the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after purchasing an additional 423 shares in the last quarter. Finally, KBC Group NV bought a new stake in Soleno Therapeutics during the 2nd quarter worth approximately $77,000. 97.42% of the stock is owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.